Research progress in co-delivery of gene and chemotherapy drugs with cationic liposome carrier for cancer therapy.
- Author:
Wei-guang CHEN
1
;
Yuan-gang LIU
;
Shi-bin WANG
;
Ai-zheng CHEN
Author Information
1. Department of Bioengineering and Biotechnology, Huaqiao University, Xiamen 361021, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
therapeutic use;
Cations;
Cell Line, Tumor;
DNA;
administration & dosage;
genetics;
Drug Carriers;
Drug Delivery Systems;
Gene Transfer Techniques;
Genetic Therapy;
methods;
Humans;
Liposomes;
administration & dosage;
chemistry;
Neoplasms;
therapy;
RNA, Small Interfering;
administration & dosage;
genetics
- From:
Acta Pharmaceutica Sinica
2012;47(8):986-992
- CountryChina
- Language:Chinese
-
Abstract:
Despite recent advances in conventional therapeutic approaches for cancer, the efficacy of chemotherapy for cancer is limited due to the drug resistance and toxic side effects during treatment. To overcome drug resistance, higher doses of the toxic chemotherapy drugs are frequently administered, thus leading to even severe adverse side effects, which have limited their clinical application. Cationic liposome as a novel non-viral carrier for co-delivery of gene and chemotherapy drugs in cancer gene therapy has already attracted more and more attention in recent years. Most importantly, this combined strategy can generate a significant synergistic effect, which can silence the related gene expression and increase the concentration of the intracellular chemotherapy drugs. This approach allows the use of a much lower dose of the chemotherapy drugs to achieve same therapeutic effect, which may have the potential for overcoming some major limitations of the conventional chemotherapy. In conclusion, co-delivery of gene and chemotherapy drugs with cationic liposome delivery system will play a vital role in the future and especially could be a promising clinical treatment for drug-resistant tumors.
